Pfizer takeover bid: MPs write to Willetts to sound warnings

A committee of MPs has written to David Willetts over the potential risks to UK science of the proposed takeover of AstraZeneca by US giant Pfizer.

May 15, 2014

The House of Commons Science and Technology Committee says in the letter that the short-term assurances Pfizer has given the government about research and development capacity can be of “little value” as the pharmaceutical industry measures progress in “decades rather than years”.

The letter, signed by the committee’s chair, Labour MP Andrew Miller, says that the pharmaceutical industry is “vital” to UK science and accounts for around 25 per cent of all commercial research and development. It also employs 2,000 “highly skilled” British scientists.

“AstraZeneca forms an extremely important part of this landscape. As such, the national stake in the proposed transaction with Pfizer is unusually high: any threat to AstraZeneca’s research capacity must, to an extent, be considered a threat to UK science,” the letter says.

The MPs warn Mr Willetts, the universities and science minister, that the government “cannot ignore the risks”.

“Science is a long-term enterprise and it requires a genuinely long-term commitment. We are not yet convinced that this is what Pfizer is offering,” the letter says.

Pfizer has pledged to base 20 per cent of its research and development staff in the UK for five years in the event of a takeover.

But the chief executive of the company, Ian Read, admitted when grilled by the Commons Business, Innovation and Skills committee on 13 May that the research and development spend of any combined company would be reduced.

The MPs from the Science and Technology Committee say that Pfizer should “strengthen” and “lengthen” the promises it has made to the government. They add that the government must be willing and able to hold Pfizer to account if needed.

“We support the Government’s efforts to attract foreign investment, but this must not be at the expense of UK science,” the letter concludes.

holly.else@tsleducation.com

You've reached your article limit.

Register to continue

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments
Register

Reader's comments (1)

Too little of UK State funded research in our universities seems to have translated across to industry and commerce. Moreover much of the latter appears not to have developed the necessary matching R&D capability, pharmaceuticals perhaps being an exception, hence presumably the current M&A concerns. Maybe more self supporting Research Institutes and Catapult centres combining successful university research teams and industrial collaborators will better drive QR/HEIF/RC basic research forward to commercialisation, so that we eventually have strong R&D in more sectors.

Have your say

Log in or register to post comments

Featured Jobs

Most Commented

Monster behind man at desk

Despite all that’s been done to improve doctoral study, horror stories keep coming. Here three students relate PhD nightmares while two academics advise on how to ensure a successful supervision

celebrate, cheer, tef results

Emilie Murphy calls on those who challenged the teaching excellence framework methodology in the past to stop sharing their university ratings with pride

Sir Christopher Snowden, former Universities UK president, attacks ratings in wake of Southampton’s bronze award

Reflection of man in cracked mirror

To defend the values of reason from political attack we need to be more discriminating about the claims made in its name, says John Hendry

But the highest value UK spin-off companies mainly come from research-intensive universities, latest figures show